Beyond CAR-T and oncology: broadening chimeric antigen receptor technologies across cell types and diseases - PubMed
5 hours ago
- #CAR-engineered cells
- #cancer treatment
- #immunotherapy
- CAR-engineered immune cells have revolutionized cancer immunotherapy, expanding beyond CAR-T cells to various cellular platforms.
- Seven FDA-approved CAR-T cell products show efficacy in hematologic malignancies but face challenges like toxicities, solid tumor resistance, and manufacturing issues.
- Research is extending CAR engineering to alternative cell types, including unconventional T cells, NK cells, macrophages, neutrophils, dendritic cells, and non-immune platforms.
- Each cell type offers unique antitumor mechanisms, persistence, safety, and manufacturing requirements, addressing different therapeutic needs.
- CAR technology shows potential beyond oncology, including autoimmune diseases, infections, cardiac fibrosis, and senescence-associated disorders.
- The review highlights recent advances in CAR platform diversity, optimization opportunities, and future therapeutic applications.